DSIP vs Icotrokinra
Overview
DSIP is primarily a sleep & recovery peptide, while Icotrokinra is used for immune support.
This page compares DSIP and Icotrokinra across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| DSIP | Icotrokinra | |
|---|---|---|
| Category | Sleep & Recovery | Immune Support |
| Regulatory status (US) | Compounding (Rx) — Apr 2026 | FDA approved |
| Typical dosage | 100-300 mcg | — |
| Frequency | before bed | — |
| Reported benefits | Improved deep sleep, stress reduction, recovery enhancement, pain reduction | — |
| Reported side effects | Very well-tolerated, possible grogginess | — |
Key differences
Primary use. DSIP is categorised under Sleep & Recovery, while Icotrokinra falls under Immune Support. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. DSIP: not FDA-approved; compounding permitted with a prescription as of April 2026. Icotrokinra: FDA-approved.
Dosing. DSIP is typically dosed at 100-300 mcg (before bed). Typical dosing for Icotrokinra is not catalogued.
Can you stack them?
Some protocols combine peptides, but stacking DSIP and Icotrokinra has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between DSIP and Icotrokinra?
- DSIP is primarily a sleep & recovery peptide, while Icotrokinra is used for immune support. DSIP is not FDA-approved; compounding permitted with a prescription (as of April 2026), whereas Icotrokinra is FDA-approved for one or more indications.
- What is DSIP used for?
- Delta sleep-inducing peptide.
- What is Icotrokinra used for?
- Oral macrocyclic peptide. First-in-class IL-23 receptor antagonist. FDA approved March 17, 2026 for plaque psoriasis.
- Can you take DSIP and Icotrokinra together?
- Some users combine peptides within a single protocol, but stacking DSIP and Icotrokinra has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is DSIP or Icotrokinra FDA-approved?
- DSIP is not FDA-approved; compounding permitted with a prescription (as of April 2026). Icotrokinra is FDA-approved for one or more indications.
Read the full articles
- DSIP — full monograph: mechanism, research, dosing & references
- Icotrokinra — full monograph: mechanism, research, dosing & references